Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-β inhibitor

Clinical Cancer Research

Volumn 12, Issue 11 I, 2006, Pages 3408-3415

  Green, Lisa J ^a   Marder, Philip ^a   Ray, Chad ^a   Cook, Carolyn A ^a   Jaken, Susan ^a   Musib, Luna C ^a   Herbst, Roy S ^b   Carducci, Michael ^c   Britten, Carolyn D ^d   Basche, Michele ^e   Eckhardt, S Gail ^e   Thornton, Donald ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d UCLA MEDICAL CENTER   (United States)

^e UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; ENZASTAURIN; PHORBOL ESTER; PROTEIN KINASE C BETA; PROTEIN KINASE C INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CELL STIMULATION; CELL STRAIN U937; DISEASE MARKER; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SELECTIVITY; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HISTIOCYTIC LYMPHOMA; HUMAN; HUMAN CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TARGET CELL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CELL LINE, TUMOR; CLINICAL TRIALS, PHASE I; DEOXYCYTIDINE; ENZYME ACTIVATORS; ENZYME INHIBITORS; FLOW CYTOMETRY; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; INDOLES; LEUKOCYTES, MONONUCLEAR; MONOCYTES; NEOPLASMS; PROTEIN KINASE C; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TREATMENT OUTCOME;

EID: 33745204140     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2231     Document Type: Article

References (23)

1. Spitaler M, Cantrell DA. Protein kinase C and beyond. Nat Immunol 2004;5:785-90.
2. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998;47:859-66.
3. Hofmann J. Protein kinase C isozymes as potential targets for anticancer therapy. Curr Cancer Drug Targets 2004;4:125-46.
4. Yan Liu WS, Thompson A, Leitges M, Murray NR, Fields AP. Protein kinase C-βII regulates its own expression in rat intestinal epithelial cells and the colonic epithelium in vivo. J Biol Chem 2004;279: 45556-63.
5. Graff JR, McNulty AM, Hanna KR, et al. The protein kinase Cβ-selective inhibitor, Enzastaurin (LY317615.HCI), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005;65:7462-9.
6. Herbst RS, Thornton, DE, Kies MS, et al. Phase I study of LY317615, a protein kinase Cβ inhibitor. Proc Am Soc Clin Oncol 2002;21:82a.
7. Rademaker-Lakhai JM, Beereport L, Witteveen EO, et al. Phase I and pharmacologie study of enzastaurin HCI, gemcitabine and cisplatin. J Clin Oncol 2004;22: 3129.
8. Fine HA, Royce C, Draper D, et al. Results from phase II trial of Enzastaurin (LY317615) in patients with recurrent high grade glimomas. ASCO annual meeting. Abstract. No. 1504; 2005.
9. Sundstrom C, Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer 1976;17:565-77.
10. Chow S, Patel H, Hedley DW. Measurement of MAP kinase activation by flow cytometry using phosphospecific antibodies to MEK and ERK: potential for pharmacodynamic monitoring of signal transduction inhibitors. Cytometry 2001;46:72-8.
11. Kiley SC, Parker PJ. Differential localization of protein kinase C isozymes in U937 cells: evidence for distinct isozyme functions during monocyte differentiation. J Cell Sci 1995;108:1003-16.
12. Pongracz J, Deacon EM, Johnson GD, Burnett D, Lord JM. Doppa induces cell death but not differentiation of U937 cells: evidence for the involvement of PKC-β1 in the regulation of apoptosis. Leuk Res 1996;20:319-26.
13. Mahajna J, King P, Parker P, Haley J. Autoregulation of cloned human protein kinase Cβ and γ gene promoters in U937 cells. DNA Cell Biol 1995;14:213-22.
14. Jacobberger JW, Frisa PS, Peng Ye P, et al. Immunoreactivity of Stat5 phosphorylated on tyrosine as a cell-based measure of Bcr/Abl kinase activity. Cytometry 2003;54A:75-88.
15. Krutzik PO, Nolan Garry P, Perez OD. Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications. Clin Immunol 2004;110:206-21.
16. Perez OD, Nolan GP. Simultaneous measurement of multiple active kinase states using polychromatic flow cytometry. Nat Biotechnol 2002;20:155-62.
17. Nishikawa K, Toker A, Johannes FJ, Songyang Z, Cantley LC. Determination of the specific substrate sequence motifs of protein kinase C isozymes. J Biol Chem 1997;272:952-60.
18. Pierchala BA, Ahrens RC, Paden AJ, Johnson EM, Jr. Nerve growth factor promotes the survival of sympathetic neurons through the cooperative function of the protein kinase C and phosphatidylinositol 3-kinase pathways. J Biol Chem 2004;279:27986-93.
19. Iwabu A, Smith K, Allen FD, Lauffenburger DA, Wells A. Epidermal growth factor induces fibroblast contractility and motility via a protein kinase C δ-dependent pathway. J Biol Chem 2004;279: 14551-60.
20. Jones ML, Craik JD, Gibbins JM, Poole AW. Regulation of SHP-1 tyrosine phosphatase in human platelets by serine phosphorylation at its C terminus. J Biol Chem 2004;279:40475-83.
21. Su TT, Guo B, Kawakami Y, et al. PKC-β controls IκB kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol 2002;3: 780-6.
22. Chang ZL, Beezhold DH. Protein kinase C activation in human monocytes: regulation of PKC isoforms. Immunology 1993;80:360-6.
23. Desplat VL, Belloc F, Chollet C, et al. Rapid detection of phosphotyrosine proteins by flow cytometric analysis in Bcr-Abl-positive cells. Cytometry 2004; 62A:35-45.